Navigation Links
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
Date:12/10/2010

SAN ANTONIO Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.

"So far, no efficacy data from Phase III trials have been reported for early breast cancer. This will be the first," said von Minckwitz. "If the pathological complete response rate is higher with bevacizmab than without bevacizumab, it will provide a new option to improve neoadjuvant treatment in HER2-negative breast cancer."

Bevacizumab is currently approved in the United States in combination with paclitaxel for the first-line treatment of metastatic breast cancer. In July 2010, the Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12 to 1 to eliminate this indication from the treatment label of bevacizumab.

"A negative or positive result might have a significant effect on this picture," said von Minckwitz. "However, pathological response as a surrogate for outcome is only confirmed for chemotherapy. Long-term follow up, as well as results from adjuvant studies have to be awaited."

The researchers investigated whether adding bevacizumab to treatment with four cycles of epirubicin/cyclophosphomide, followed by four cycles of docetaxel improved the rate of pathological complete response, which was defined as no invasive or non-invasive residual cancer in the breast or nodes.

Between May 2007 and June 2010, 944 patients were assigned chemotherapy treatment with epirubicin/cyclophosphamide followed by docetaxel; 945 patients were assigned
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony for ... Wednesday, April 22. , Johnson & Wales becomes the first ... re-alignment of Interstate-195. JWU’s new academic building, which will be ... Providence, is scheduled to be completed in July 2016. It ... purchased in 2012. , “It has long been our hope ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
(Date:5/4/2015)... Glendale, CA (PRWEB) May 04, 2015 ... intensify as baby boomers join the ranks of senior ... unprecedented demand on an already over-burdened healthcare system. Additionally, ... qualified staff to replace them. Per the U.S. Census ... is expected to increase 75% by 2050 while those ...
(Date:5/4/2015)... 2015 EY today announced that Kevin ... finalist for the EY Entrepreneur Of The Year® 2015 ... program recognizes entrepreneurs who demonstrate excellence and extraordinary success ... commitment to their businesses and communities. Mr. MacDonald ... independent judges. Award winners will be announced on ...
Breaking Medicine News(10 mins):Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2
... following is a,memorandum to editorial writers and columnists:, ... Communications,Director, SUBJECT: Katrina Storm Warning, On ... New Orleans,and the Gulf Coast are struggling to ... disasters in U.S. history. Disaster often strikes suddenly,and ...
... A new study released on,Monday, August 27, 2007 ... Prevention of Work-Related Musculoskeletal Disorders, held in,Boston, highlights ... both. Dr. Susan Buchanan, University of Illinois at,Chicago ... that raise,many questions as to why certain workers ...
... culprits behind the increase, , , THURSDAY, Aug. 30 (HealthDay ... sport early -- playing year-round, joining competitive club or ... believing they,ll put themselves on the fast track to ... , But for too many of these kids, that ...
... researchers say more study is needed to prove a link ... in damp, moldy homes may be prone to depression, a ... an analysis of mold and health conditions in several cities ... lead to the addition of emotional problems to the list ...
... The Mutter Museum will be taking its two Presidential ... the Arden Theater,s ASSASSINS on September 19., PHILADELPHIA, ... Arden Theater will display the actual remains of two,of ... opening,night of the Arden,s production of Assassins, Wednesday, September ...
... Calif., Aug. 30 Omnicell, Inc.,(Nasdaq: OMCL ) ... safety and operational efficiency in healthcare,facilities, today announced that ... vice president & CFO will present at the Thomas ... Boston, Mass.,on Wednesday, September 5, 2007 at 11:30 a.m. ...
Cached Medicine News:Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 4Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 5Health News:New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites 2Health News:New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites 3Health News:More Kids Are Suffering Sports Injuries 2Health News:More Kids Are Suffering Sports Injuries 3Health News:Damp, Moldy Homes May Cause Depression 2Health News:Damp, Moldy Homes May Cause Depression 3Health News:Damp, Moldy Homes May Cause Depression 4Health News:The Mutter Assassins Go to the Theater! 2Health News:The Mutter Assassins Go to the Theater! 3Health News:Omnicell to Present at Thomas Weisel Healthcare Conference 2007 2
(Date:5/4/2015)... TORONTO , May 4, 2015 ... that it intends to dividend to its stockholders a ... a definitive licensing agreement to license its RapidMist™ buccal ... (OTCQB:SMFI). As announced on April 23, 2015, ... respect of the licensing of its RapidMist™ buccal drug ...
(Date:5/4/2015)... 4, 2015 Rogne Bioscience, a privately-held biotechnology ... that preclinical and mechanism of action data will be ... Investigative Dermatology (SID) Annual Meeting being held May 6-9, ... Georgia . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... RON2315, a novel, low MW (<1700 daltons) peptide as ...
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... Colo., May 13, 2011 Mesa Laboratories, Inc. (NASDAQ: ... of Directors has declared a regular quarterly cash dividend ... on June 15, 2011 to shareholders of record at ... Mesa Laboratories develops, acquires, manufactures and markets electronic ...
... Spine, a medical device company that designs, develops, manufactures ... disorders, today announced that the Company presented an overview ... the 6th Annual Spine Technology Summit, hosted by P&M ... California. "Life Spine has an extremely active ...
Cached Medicine Technology:
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: